Advanced in Alveolar Soft Part Sarcoma

Dr. Joshua M. Mammen

Surgical Oncology
Unmc Physicians
987400 Nebraska Medical Ctr, Unmc Physicians Nebraska M, 
Omaha, NE 
Accepting New Patients
Offers Telehealth
Advanced in Alveolar Soft Part Sarcoma
Unmc Physicians
987400 Nebraska Medical Ctr, Unmc Physicians Nebraska M, 
Omaha, NE 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Joshua Mammen is a Surgical Oncologist in Omaha, Nebraska. Dr. Mammen is rated as an Advanced provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. His top areas of expertise are Merkel Cell Carcinoma, Melanoma, Eccrine Porocarcinoma, Lymphadenectomy, and Ureteroscopy. Dr. Mammen is currently accepting new patients.

His clinical research consists of co-authoring 27 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 1 clinical trial in the study of Alveolar Soft Part Sarcoma.

Specialties
Surgical Oncology
Licenses
Surgery in TX
Hospital Affiliations
Bellevue Medical Center, LLC
The Nebraska Medical Center
Languages Spoken
English
American Sign Language
Burmese
French
Malayalam
Malayan
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellmark
  • HMO
  • POS
View 5 Less Insurance Carriers -

Locations

UNMC PHYSICIANS
987400 Nebraska Medical Ctr, Unmc Physicians Nebraska M, Omaha, NE 68198
Other Locations
UNMC PHYSICIANS
2500 Bellevue Medical Ctr Dr, Bellevue, NE 68123

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma
A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Biological, Radiation
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Temozolomide
Study Phase: Phase 2
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Other, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2025
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Doxorubicin, Ifosfamide, Pazopanib
Study Phase: Phase 2/Phase 3
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
Enrollment Status: Completed
Publish Date: April 23, 2025
Intervention Type: Radiation, Drug
Study Phase: Phase 3
View 6 Less Clinical Trials

27 Total Publications

International Survey on Evidence for Index Lymph Node Surgery After Neoadjuvant Systemic Therapy for Stage III Melanoma.
International Survey on Evidence for Index Lymph Node Surgery After Neoadjuvant Systemic Therapy for Stage III Melanoma.
Journal: Annals of surgical oncology
Published: August 12, 2025
Similar Doctors
Advanced in Alveolar Soft Part Sarcoma
Dr. George W. Dittrick
Surgical Oncology | Emergency Medicine | General Surgery
Advanced in Alveolar Soft Part Sarcoma
Dr. George W. Dittrick
Surgical Oncology | Emergency Medicine | General Surgery

Physicians Clinic Inc

8111 Dodge St, Suite 263, 
Omaha, NE 
 (3.4 miles away)
402-354-8163
Languages Spoken:
English
See accepted insurances
Accepting New Patients

George Dittrick is a Surgical Oncologist and an Emergency Medicine provider in Omaha, Nebraska. Dr. Dittrick is rated as a Distinguished provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. His top areas of expertise are Familial Pancreatic Cancer, Pancreatic Cancer, Pancreatic Adenoma, Pancreatectomy, and Small Bowel Resection. Dr. Dittrick is currently accepting new patients.

Experienced in Alveolar Soft Part Sarcoma
Dr. Quan P. Ly
Surgical Oncology | General Surgery
Experienced in Alveolar Soft Part Sarcoma
Dr. Quan P. Ly
Surgical Oncology | General Surgery

Unmc Physicians

987400 Nebraska Medical Ctr, Unmc Physicians Nebraska M, 
Omaha, NE 
 (0.1 miles away)
402-559-4000
Languages Spoken:
English, American Sign Language, Vietnamese
See accepted insurances
Accepting New Patients

Quan Ly is a Surgical Oncologist and a General Surgeon in Omaha, Nebraska. Dr. Ly is rated as a Distinguished provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. Her top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Colorectal Cancer, Splenectomy, and Pancreatectomy. Dr. Ly is currently accepting new patients.

Advanced in Alveolar Soft Part Sarcoma
Dr. Robert H. Lindau
Plastic Surgery | Surgical Oncology | General Surgery
Advanced in Alveolar Soft Part Sarcoma
Dr. Robert H. Lindau
Plastic Surgery | Surgical Oncology | General Surgery

Nebraska Methodist Hospital

8303 Dodge St, 
Omaha, NE 
 (3.4 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Robert Lindau is a Plastic Surgeon and a Surgical Oncologist in Omaha, Nebraska. Dr. Lindau is rated as a Distinguished provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. His top areas of expertise are Adenoid Cystic Carcinoma, Acinic Cell Carcinoma of Salivary Glands, Salivary Gland Tumors, Gastrostomy, and Tissue Biopsy. Dr. Lindau is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mammen's expertise for a condition
ConditionClose
    View All 21 Advanced Conditions
    View All 14 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile